Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 165 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 279 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
MOLECURE Aktie jetzt für 0€ handeln | |||||
31.07.24 | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 476 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CO.DON | 0,047 | +13,41 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,461 | -0,67 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
IMMATICS | 4,700 | +1,42 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
ALDEYRA | 3,246 | +0,65 % | Aldeyra-Aktie steigt nach FDA-Vereinbarung zum Krebsmedikament-Studiendesign | ||
MEDIFAST | 11,435 | -1,38 % | MEDIFAST INC - 8-K, Current Report | ||
PHARMING | 0,940 | +0,80 % | Pharming Group N.V. - 6-K, Report of foreign issuer | ||
COHERUS ONCOLOGY | 0,643 | +1,42 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
ORUKA THERAPEUTICS | 9,550 | +1,06 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two... ► Artikel lesen | |
DBV TECHNOLOGIES | 1,540 | -0,90 % | DBV Technologies S.A.: DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years Old | Châtillon, France, June 25, 2025
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years Old
First subject screened... ► Artikel lesen | |
INNOVIVA | 16,900 | -1,74 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
ARMATA PHARMACEUTICALS | 1,530 | -4,38 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met
AP-SA02 arm significantly improved clinical outcomes... ► Artikel lesen | |
BRAINSTORM CELL THERAPEUTICS | 1,050 | -100,00 % | BRAINSTORM CELL THERAPEUTICS INC. - 8-K, Current Report | ||
SIGA TECHNOLOGIES | 6,465 | -1,60 % | SIGA Reports Record Profits for Latest Fiscal Year | ||
LIQUIDIA | 11,250 | +0,54 % | Liquidia receives $50 million funding after court denies injunction | ||
Q32 BIO | 1,280 | -0,78 % | Q32 Bio Inc. - 8-K, Current Report |